Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd. has reported a robust start to FY25 with a 14% year-over-year revenue increase to ₹76,727 Mn, bolstered by a strong generics business. The company’s gross margin improved to 60.4%, while profits after tax saw a slight dip of 1% year-over-year but increased by 7% from the previous quarter. These financial gains underscore Dr. Reddy’s commitment to growth through strategic investments in biologics, consumer healthcare, and innovation.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
